Skip to content

The clinical efficacy and mechanism of 40 Hz electroacupuncture stimulation induced gamma oscillations to promote the rehabilitation of upper limb motor function in stroke patients

The clinical efficacy and mechanism of 40 Hz electroacupuncture stimulation induced gamma oscillations to promote the rehabilitation of upper limb motor function in stroke patients

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400082208
Enrollment
Unknown
Registered
2024-03-22
Start date
2024-03-24
Completion date
Unknown
Last updated
2024-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

stroke

Interventions

treatment group:40 Hz electroacupuncture stimulates "Quchi" acupoint
control group:routine rehabilitation

Sponsors

Shanghai University of Traditional Chinese Medicine,
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Meet the criteria for ischemic stroke in the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2018, and confirmed by CT or MRI of the head; (2) Unilateral hemiplegia; (3) The onset time was 2 weeks to 3 months, and the vital signs were stable; (4) Age 45-80 years old; (5) Clinical manifestations of upper limb motor dysfunction; (6) Can sit independently for 1 hour or more; (7) Stable condition, clear consciousness, no aphasia, disorder, able to understand the content of the scale and cooperate with examination and treatment; (8) The patient has not taken any sedative medication or muscle relaxant for 2 weeks; (9) Informed consent and signed written informed consent.

Exclusion criteria

Exclusion criteria: (1) The condition is critical or the condition is not stable in the acute stage; (2) Those who have deafness, aphasia or severe cognitive impairment and are difficult to communicate normally; (3) Patients with systolic blood pressure > 180 mmHg or diastolic blood pressure > 110 mmHg, patients with severe cardiovascular, liver, kidney, blood, digestive, respiratory and other primary diseases, patients with mental illness, malignant tumors, venous thrombosis, osteoporosis, severe bleeding tendency and infection at the treatment site; (4) Those who are unable to recover with the study protocol or participate in other clinical experiments within 3 months or receive other related treatments in the middle of the study, which may affect the efficacy judgment of this study; (5) Dystonia and previous motor dysfunction caused by other reasons; (6) Pregnant and lactating women; (7) Hemiplegia upper limb with previous trauma and bone and joint diseases; (8) severe spasticity, i.e., modified Ashworth grade above grade III.; (9) Placement of pacemakers, cochlear implants and other instruments and equipment in the body; (10) Previous vagus nerve surgery; (11) Have taken Chinese or Western sedative drugs and muscle relaxants within 2 weeks.

Design outcomes

Primary

MeasureTime frame
Fugl-Meyer Assessment Upper Extremity Scale;

Secondary

MeasureTime frame
National Institutes of Health Stroke Scale;Mini-mental State Examination;Modified Barthel Index;electroencephalogram;

Countries

China

Contacts

Public ContactJun Hu

The Second Rehabilitation Hospital of Shanghai

lukehoo@126.com+86 158 0037 1522

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026